Skip to content

Kiniksa Pharmaceuticals International

US · KNSA #1938 by market cap Listed 2018
93.90 +0.36 +0.38%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 93.00 -0.57%
After-hours 93.90 0.00%
Overnight 93.09 -0.48%
98.7646.9293.902026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on KNSA?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is +73.0% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 5.5% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bullish
  • Price is above its 20-day average and above its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days B → B

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2849 U.S. stocks StockVane covers.

Last computed: 2026-11-21 14:27 UTC

Data coverage: 6 of 6 factors. Missing data is not a zero score.

Overall A-
ValuationGrowthProfitMomentumHealthAnalyst
Valuation D-

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 71.1x Better than 6%
Forward P/E 53.5x Better than 7%
Price / Sales 8.0x Better than 13%
P/E vs own 5-yr range 75th pctl Better than 32%
Growth A-

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 45.5% Better than 95%
Net income CAGR (3Y) -31.5% Better than 11%
Free cash flow CAGR (3Y) 188.1% Better than 98%
Profitability B

How much profit the business keeps from each dollar of sales and capital.

Gross margin 54.7% Better than 69%
Operating margin 11.4% Better than 55%
Net margin 8.7% Better than 56%
Return on equity 11.7% Better than 58%
Return on invested capital 11.5% Better than 74%
Momentum A+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return 18.8% Better than 96%
6-month return 76.4% Better than 98%
12-month return (ex latest month) 94.3% Better than 95%
Distance below 52-week high 5.5% Better than 94%
Financial Health A+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 3.8x Better than 80%
Debt to assets 1.2% Better than 91%
Free cash flow / net income 231.2% Better than 81%
Analyst View B-

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 13.1% Better than 19%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -2.53%
1M +12.90%
3M +19.66%
6M +72.98%
YTD +127.62%
1Y +126.31%
3Y +492.77%
5Y +669.63%

Key statistics

Price & volume

Prev close
93.54
Open
93.48
Day range
92.68 - 95.29
Avg price
94.06
Volume
545.20K
Turnover
51.28M
Amplitude
2.79%
52-week range
37.02 - 99.31

Valuation

P/E
125.19
P/E (TTM)
71.13
P/B
10.39
EPS
0.75
Net profit
58.93M
Net assets
710.21M

Share structure

Market cap
7.38B
Float cap
4.18B
Shares out
78.57M
Float shares
44.56M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2018-05-24
52-week range 91% of range
37.02 99.31

5.5% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-5.85M net over the window

Short interest

Shares short
4.29M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Kiniksa Pharmaceuticals International (KNSA)?

Kiniksa Pharmaceuticals International last traded at 93.90. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Kiniksa Pharmaceuticals International's market cap?

About 7.38B.

What is the P/E ratio of Kiniksa Pharmaceuticals International?

The trailing twelve-month P/E is 71.13, above its own 5-year average of 25.68 — toward the top of its historical range (75.20% percentile). See the Valuation tab for the full history.

Does Kiniksa Pharmaceuticals International pay a dividend?

Kiniksa Pharmaceuticals International does not currently pay a regular dividend.

Is Kiniksa Pharmaceuticals International a buy according to analysts?

The consensus of 5 analysts is a Buy rating, with an average 12-month price target of 106.20, which implies 13.1% upside from the current price. This is not investment advice.

What is Kiniksa Pharmaceuticals International's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Kiniksa Pharmaceuticals International a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 20:02:29 · For reference only, not investment advice and not tailored to your situation.

Kiniksa Pharmaceuticals International discussion 0 comments

Add a comment